Heartworm disease can have a devastating effect on your pet's health. National Heartworm Awareness Month, observed annually in April, reminds pet owners about the health dangers this preventable d ...View Article
You are using an outdated browser. Please upgrade your browser to improve your experience.
TANOVEA-CA1 (Lymphoma Treatment)
Maine Veterinary Medical Center's Oncology Department is thrilled to offer Tanovea-CA1, the first ever FDA conditionally approved lymphoma treatment for dogs. MVMC offers a number of drugs to treat canine lymphoma and is excited to offer the most recent development.
Lymphoma, also known as lymphoscaroma is a type of cancer affecting canines. The active ingredient in Tanovea-CA1, rabacfosadine, is a substance that kills rapidly growing lymphoma cancer cells.
If you have any questions regarding the drug or patients that may be eligible, please contact us.
How does TANOVEA-CA1 work?
Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.